Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing.

doi:10.1016/j.jtho.2021.01.1615

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 May 2021

Yang Yunpeng, Huang Jie, Wang Tao, Zhou Jianya, Zheng Jing, Feng Jifeng, Zhuang Wu, Chen Jianhua, Zhao Jun, Zhong Wei, Zhao Yanqiu, Zhang Yiping, Song Yong, Hu Yi, Yu Zhuang, Gong Youling, Chen Yuan, Ye Feng, Zhang Shucai, Cao Lejie, Fan Yun, Wu Gang, Guo Yubiao, Zhou Chengzhi, Ma Kewei, Fang Jian, Feng Weineng, Liu Yunpeng, Zheng Zhendong, Li Gaofeng, Wang Huijie, Cang Shundong, Wu Ning, Song Wei, Liu Xiaoqing, Zhao Shijun, Ding Lieming, Mao Li, Selvaggi Giovanni, Zhu Larry, Xiao Shanshan, Yuan Xiaobin, Shen Zhilin, Zhang Li

Abstract excerpt

INTRODUCTION: By implementing dynamic circulating tumor DNA (ctDNA) analysis, we explored the impact of TP53 mutations on tumor evolution and resistance mechanisms to ensartinib in patients with ALK-positive NSCLC. METHODS: In a multicenter phase 2 trial, patients with ALK-positive NSCLC who progressed on crizotinib were treated with ensartinib. Blood samples for ctDNA analysis were collected at baseline, cycle 3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anaplastic Lymphoma Kinase

Share to Circulating Tumor DNA

Share to Drug Resistance, Neoplasm

Share to Lung Neoplasms

Share to Mutation

Share to Piperazines

Share to Protein Kinase Inhibitors

Share to Pyridazines

Source

Open in PubMed

Identifiers

PMID: 33588113
DOI: 10.1016/j.jtho.2021.01.1615

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing.PMID 33588113Read ↗

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.Semantic proximity Read ↗

Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator).Semantic proximity Read ↗

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.Semantic proximity Read ↗

EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcomeSemantic proximity Read ↗

Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patientsSemantic proximity Read ↗

Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.Semantic proximity Read ↗

The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung CancerSemantic proximity Read ↗

Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.Semantic proximity Read ↗

Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer.Semantic proximity Read ↗

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.Semantic proximity Read ↗

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.Semantic proximity Read ↗

Assessing In House Comprehensive Genomic Profiling by Liquid Biopsy for NSCLC PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.